Diagnosis and treatment system for "reward deficiency syndrome" (RDS) and related behaviors

An intravenous formulation comprising:

• (a) an opiate destruction-inhibiting amount of at least one substance which inhibits the enzymatic destruction of neuropeptidyl opiate, said substance being selected from the group consisting of amino acids, peptides, and structural analogues or derivatives thereof:
• b) a neurotransmitter synthesis-promoting amount of at least one neurotransmitter precursor selected from the group consisting of dopamine precursors L-Tyr, L-Phe and L-dopa, serotonin precursors L-Trp and 5-hydroxytryptophan, and gamma amino butyric acid (GABA) precursors L-glutamine, L-glutamic acid, and L-glutamate;
• and
• c) a tryptophan concentration enhancing amount of chromium picolinate or chromium nicotinate;
• wherein the amount of said substance and said neurotransmitter precursor and said chromium compound being effective in reducing a subject's RDS behaviors.